CytoSorbents announces recent data presentation on CytoSorb

CytoSorbents announces the recent data presentation entitled “Early CABG with Intraoperative Haemoadsorption in Patients on Ticagrelor: The Safe and Timely Antithrombotic Removal Registry,” at the international EuroPCR 2024 conference in Paris, France – the world-leading course in interventional cardiovascular medicine with over 12,000 attendees – where it was also selected as a top 5 finalist in the best scientific abstract competition. In these 102 patients, the mean time from the last dose of ticagrelor was 22.8 hours. The mean age was 63.8 years, approximately 80% were male, and 43% had diabetes: There were no device-related adverse events reported by investigators using intraoperative CytoSorb during CABG surgery; Overall, severe bleeding according to the Universal Definition of Perioperative Bleeding criteria occurred in 9.8% of patients; In a subgroup analysis, the study population was divided into 2 groups. Group 1 comprised patients operated less than24 hours from last ticagrelor dose and Group 2 comprised patients operated more than 24 but less than 72 hours from last dose. Demographics were similar between the two groups, however, Group 1 patients had significantly higher perioperative risk compared with Group 2 patients based upon the more frequent need for more hazardous emergency surgery and the higher baseline predicted surgical risk according to the standardized EuroScore II score. Expectedly, higher risk patients in Group 1 had a higher rate of severe bleeding compared with Group 2 patients